IN8bio Inc (INAB)
1.09
-0.59
(-35.12%)
USD |
NASDAQ |
Jun 14, 16:00
1.12
+0.03
(+2.75%)
After-Hours: 20:00
IN8bio Research and Development Expense (Quarterly): 4.903M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.903M |
| December 31, 2023 | 4.522M |
| September 30, 2023 | 3.786M |
| June 30, 2023 | 4.134M |
| March 31, 2023 | 4.385M |
| December 31, 2022 | 3.922M |
| September 30, 2022 | 4.255M |
| June 30, 2022 | 3.504M |
| March 31, 2022 | 2.381M |
| Date | Value |
|---|---|
| December 31, 2021 | 2.687M |
| September 30, 2021 | 1.35M |
| June 30, 2021 | 2.064M |
| March 31, 2021 | 1.245M |
| December 31, 2020 | 1.485M |
| September 30, 2020 | 1.057M |
| June 30, 2020 | 1.784M |
| March 31, 2020 | 1.052M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.052M
Minimum
Mar 2020
4.903M
Maximum
Mar 2024
2.854M
Average
2.687M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Jaguar Health Inc | 4.312M |
| Aptevo Therapeutics Inc | 3.752M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |
| iBio Inc | 0.904M |